Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...

With the investment, the production capacity will have "a considerable and significant increase," said Reinaldo Costa, ...

Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time ...

Novo Nordisk may be reorganizing its early-stage ... programs like its early-stage Parkinson’s cell therapy or oncology work? “I think it’s fair to say they are not in the center of our ...

executive vice president for development at Novo Nordisk. “We look forward to building on United Biotechnology’s scientific work and further exploring the potential best-in-class properties of ...

Novo Nordisk has been on the hunt for differentiated obesity drugs that could complement its blockbuster GLP-1 agonist, Wegovy. It’s found a contender with preclinical data indicating it can ...

Novo Nordisk (NVO) announced on Saturday that a late-stage trial for its popular weight loss therapy Ozempic in adults with type 2 diabetes and a vascular disorder known as peripheral artery ...

Well before market open that morning, Morgan Stanley's Thibault Boutherin knocked his Novo Nordisk price target down to 600 Danish kroner ($86.67) per share; previously, this number was 700 kroner ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

According to the heat map I created, which distributes the winner by each parameter, Eli Lilly scored 7 points, while Novo Nordisk only 2. As a result, Eli Lilly is the winner in this category by ...